Overview

Effectiveness of Mucolox® and Clonazepam in Treatment of Burning Mouth Syndrome

Status:
Withdrawn
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
What affect does the use of a mucoadhesive drug delivery system (Mucolox®) compounded with clonazepam have in the treatment of burning mouth syndrome? There are no clinical trials reported in the literature that evaluate the use of a mucoadhesive vehicle to deliver clonazepam into the oral cavity and treat burning mouth syndrome. The use of a mucoadhesive may help to increase surface contact and elicit a greater reduction in symptoms.
Phase:
Phase 4
Details
Lead Sponsor:
University of Alberta
Treatments:
Clonazepam